(Circulation. 1996;94:1513-1518.)
© 1996 American Heart Association, Inc.
Articles |
Expression of Angiotensin-Converting Enzyme in Remaining Viable Myocytes of Human Ventricles After Myocardial Infarction
the Division of Cardiology (S.H., H.Yasue, K.F., K.N., K.K.) and the Department of Pharmacology (H.Yamamoto, E.M.), Kumamoto University School of Medicine, and the Division of Cardiovascular Surgery, Kumamoto Chuo Hospital (R.S.), Kumamoto, Japan.
Correspondence to Hirofumi Yasue, MD, Division of Cardiology, Kumamoto University School of Medicine, 1-1-1, Honjo, Kumamoto City, Kumamoto 860, Japan.
Background Local ACE in the heart may be important in the pathophysiological state after myocardial infarction (MI). It is unknown, however, whether ACE is expressed in myocytes of the human heart.
Methods and Results Using a newly generated polyclonal antibody to a synthetic peptide corresponding to part of the human endothelial ACE sequence, we examined the localization of ACE in left ventricles of patients (n=10) with MI obtained at left ventricular aneurysmectomy or autopsy and in the hearts of control subjects at autopsy (n=10). The avidin–biotinylated peroxidase complex method was used for the immunohistochemical staining for ACE. In the left ventricles, positively stained myocytes for ACE were found in 8 of the 10 patients with MI. ACE immunoreactivity was seen in the remaining viable myocytes located near the infarct scar of the aneurysmal left ventricle and in nonmyocytes such as fibroblasts, macrophages, vascular smooth muscle cells, and endothelial cells within the scarred tissue. On the other hand, no immunoreactivity for ACE was detected in the ventricular myocytes of all control hearts obtained at autopsy.
Conclusions We observe immunohistochemical staining for ACE in the left ventricular myocytes of the region adjacent to the infarct scar and in nonmyocytes. These results indicate that ACE is markedly increased on the edge of the infarct scar and suggest that local ACE may be important in the ventricular remodeling after MI.
Key Words: angiotensin • myocardial infarction • aneurysm • immunohistochemistry
This article has been cited by other articles:
 |
|
 |
|
  S. A. Saha, J. Molnar, and R. R. Arora Tissue ACE Inhibitors for Secondary Prevention of Cardiovascular Disease in Patients With Preserved Left Ventricular Function: A Pooled Meta-analysis of Randomized Placebo-controlled Trials Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 192 - 204. [Abstract] [PDF]
|
|
|
|
 |
|
 M. P. Ocaranza, I. Godoy, J. E. Jalil, M. Varas, P. Collantes, M. Pinto, M. Roman, C. Ramirez, M. Copaja, G. Diaz-Araya, et al. Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted Rat Hypertension, October 1, 2006; 48(4): 572 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Burrell, J. Risvanis, E. Kubota, R. G. Dean, P. S. MacDonald, S. Lu, C. Tikellis, S. L. Grant, R. A. Lew, A. I. Smith, et al. Myocardial infarction increases ACE2 expression in rat and humans Eur. Heart J., February 2, 2005; 26(4): 369 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nakamura, M. Yoshimura, M. Nakayama, T. Ito, Y. Mizuno, E. Harada, T. Sakamoto, Y. Saito, K. Nakao, H. Yasue, et al. Possible Association of Heart Failure Status With Synthetic Balance Between Aldosterone and Dehydroepiandrosterone in Human Heart Circulation, September 28, 2004; 110(13): 1787 - 1793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yoshimura, S. Nakamura, T. Ito, M. Nakayama, E. Harada, Y. Mizuno, T. Sakamoto, M. Yamamuro, Y. Saito, K. Nakao, et al. Expression of Aldosterone Synthase Gene in Failing Human Heart: Quantitative Analysis Using Modified Real-Time Polymerase Chain Reaction J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3936 - 3940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fielitz, S. Hein, V. Mitrovic, R. Pregla, H. R. Zurbrugg, C. Warnecke, J. Schaper, E. Fleck, and V. Regitz-Zagrosek Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1443 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. van Kats, D. J. Duncker, D. B. Haitsma, M. P. Schuijt, R. Niebuur, R. Stubenitsky, F. Boomsma, M. A. D. H. Schalekamp, P. D. Verdouw, and A. H. J. Danser Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade Prevent Cardiac Remodeling in Pigs After Myocardial Infarction : Role of Tissue Angiotensin II Circulation, September 26, 2000; 102(13): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. De Mello and A. H. J. Danser Angiotensin II and the Heart : On the Intracrine Renin-Angiotensin System Hypertension, June 1, 2000; 35(6): 1183 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Moriyama, H. Yasue, M. Yoshimura, Y. Mizuno, K. Nishiyama, R. Tsunoda, H. Kawano, K. Kugiyama, H. Ogawa, Y. Saito, et al. The Plasma Levels of Dehydroepiandrosterone Sulfate Are Decreased in Patients with Chronic Heart Failure in Proportion to the Severity J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1834 - 1840. [Abstract] [Full Text]
|
|
|
|
|
|
A. A. Bavry, D. Li, D. S. Zander, M. I. Phillips, and J. L. Mehta Inhibition of Arterial Thrombogenesis by Quinapril but Not Losartan Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 121 - 127. [Abstract] [PDF]
|
|
|
|
 |
|
 A.H.J. Danser, J. J Saris, M. P Schuijt, and J. P van Kats Is there a local renin--angiotensin system in the heart? Cardiovasc Res, November 1, 1999; 44(2): 252 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Dostal and K. M. Baker The Cardiac Renin-Angiotensin System : Conceptual, or a Regulator of Cardiac Function? Circ. Res., October 1, 1999; 85(7): 643 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C Wollert and H. Drexler The renin-angiotensin system and experimental heart failure Cardiovasc Res, September 1, 1999; 43(4): 838 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.L. Mehta and I. Phillips Increase in Plasma Angiotensin II Levels After Chemical Blockade of AT1 Receptor Blockers, But Not With Antisense Oligodeoxynucleotide Directed at AT1 Receptor mRNA: A Major Benefit of Gene Therapy Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(3): 135 - 136. [PDF]
|
|
|
|
|
|
S. Hafizi, J. Wharton, K. Morgan, S. P. Allen, A. H. Chester, J. D. Catravas, J. M. Polak, and M. H. Yacoub Expression of Functional Angiotensin-Converting Enzyme and AT1 Receptors in Cultured Human Cardiac Fibroblasts Circulation, December 8, 1998; 98(23): 2553 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. R. M. Osterop, M. J. M. Kofflard, L. A. Sandkuijl, F. J. t. Cate, R. Krams, M. A. D. H. Schalekamp, and A. H. J. Danser AT1 Receptor A/C1166 Polymorphism Contributes to Cardiac Hypertrophy in Subjects With Hypertrophic Cardiomyopathy Hypertension, November 1, 1998; 32(5): 825 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Zisman, K. Asano, D. L. Dutcher, A. Ferdensi, A. D. Robertson, M. Jenkin, E. W. Bush, T. Bohlmeyer, M. B. Perryman, and M. R. Bristow Differential Regulation of Cardiac Angiotensin Converting Enzyme Binding Sites and AT1 Receptor Density in the Failing Human Heart Circulation, October 27, 1998; 98(17): 1735 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. van Kats, A. H. J. Danser, J. R. van Meegen, L. M. A. Sassen, P. D. Verdouw, and M. A. D. H. Schalekamp Angiotensin Production by the Heart : A Quantitative Study in Pigs With the Use of Radiolabeled Angiotensin Infusions Circulation, July 7, 1998; 98(1): 73 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. de Lannoy, A.H. J. Danser, A. M.B. Bouhuizen, P. R. Saxena, and M. A.D.H. Schalekamp Localization and Production of Angiotensin II in the Isolated Perfused Rat Heart Hypertension, May 1, 1998; 31(5): 1111 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wharton, K. Morgan, R. A. D. Rutherford, J. D. Catravas, A. Chester, B. F. Whitehead, M. R. D. Leval, M. H. Yacoub, and J. M. Polak Differential Distribution of Angiotensin AT2 Receptors in the Normal and Failing Human Heart J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 323 - 336. [Abstract] [Full Text]
|
|
|
|
|
|
H. Ju, S. Zhao, D. S Jassal, and I. M.C Dixon Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction Cardiovasc Res, August 1, 1997; 35(2): 223 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. J. Danser, C. A. M. van Kesteren, W. A. Bax, M. Tavenier, F. H. M. Derkx, P. R. Saxena, and M. A. D. H. Schalekamp Prorenin, Renin, Angiotensinogen, and Angiotensin-Converting Enzyme in Normal and Failing Human Hearts : Evidence for Renin Binding Circulation, July 1, 1997; 96(1): 220 - 226. [Abstract] [Full Text]
|
|